Research needed on psychedelic compound for opioid withdrawal
نویسندگان
چکیده
منابع مشابه
Needed: Global Collaboration for Comparative Research on Cities and Health
Over half of the world’s population lives in cities and United Nations (UN) demographers project an increase of 2.5 billion more urban dwellers by 2050. Yet there is too little systematic comparative research on the practice of urban health policy and management (HPAM), particularly in the megacities of middle-income and developing nations. We make a case for creating a global database on citie...
متن کاملOpioid tolerance or opioid withdrawal?
To the Editor: We thank Kim et al. for their recent work examining the effect of intraoperative remifentanil on postoperative analgesia in children.1 Certainly, the pharmacokinetic profile of this potent opioid is attractive in modern anesthetic practice, and a thorough understanding of the principles behind tolerance, hyperalgesia, and withdrawal of remifentanil are critical for its safe admin...
متن کاملA much-needed window on opioid diversion.
David E. Joranson, MSSW Senior Scientist, Director Pain & Policy Studies Group Paul P. Carbone Comprehensive Cancer Center University of Wisconsin School of Medicine and Public Health World Health Organization Collaborating Center for Policy and Communications in Cancer Care 406 Science Drive, Suite 202 Madison, Wisconsin 53711-1068 tel 1 608 263 7662 fax 1 608 263 0259 [email protected] www.pa...
متن کاملneeded: global collaboration for comparative research on cities and health
over half of the world’s population lives in cities and united nations (un) demographers project an increase of 2.5 billion more urban dwellers by 2050. yet there is too little systematic comparative research on the practice of urban health policy and management (hpam), particularly in the megacities of middle-income and developing nations. we make a case for creating a global database on citie...
متن کاملThe Psychedelic Renaissance: Horizons, the Fifth Annual Conference on Psychedelic Research
In the spring of 1943, a 37-year-old Swiss chemist named Albert Hofmann had “a peculiar presentiment.” He believed that he had missed something in 1938, the year when he first synthesized the twenty-fifth compound of the lysergic acid diethylamide series, LSD-25. For eight years at Sandoz Pharmaceuticals, Hofmann was in charge of the ergot project, which involved synthesizing ergotamine molecul...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Pharmacy Today
سال: 2018
ISSN: 1042-0991
DOI: 10.1016/j.ptdy.2018.06.009